Commutable patient-matrix reference material panel for validating tumor-informed ctDNA MRD assays (clinical QC material) — payer messages

Intended use: Quality control material — intended for use by molecular laboratories to monitor the analytical performance (analytical sensitivity at defined low tumor fractions, specificity, and inter-run precision) of tumor-informed circulating tumor DNA minimal residual disease assays, during assay validation and in routine run-by-run quality control. Not a calibrator, and not for use in establishing or interpreting an individual patient result.

Messages

• Billed under: Nothing. This product has no CPT (Current Procedural Terminology) or HCPCS (Healthcare Common Procedure Coding System) code and is not billed to you. A laboratory buys it as an operating input out of its own budget, and no national or local coverage determination applies to it. claim 55unconfirmed claim 14unconfirmed
• The comparator: You are not paying for a control today and you will not be paying for this one. What you pay for is the laboratory's MRD (molecular residual disease) test: Medicare's CY2026 national limitation amount for 0340U is $3,590.00 per service, a single per-test rate. claim 71verified
• Where that payment is made: The one national Medicare row for 0340U is office/non-facility — 25,746 services in 2024 and no facility row — so there is no inpatient stay or outpatient facility claim for a DRG or APC to package this into. claim 68verified
• Budget impact: None to a payer. We ask for no new code, no add-on payment and no coverage decision; whatever a control costs sits inside the per-test payment the laboratory already receives. claim 55unconfirmed
• Coverage argument: There is none to make, because nothing is being submitted for coverage. The coverage that touches this is the customer's: four active MolDX "Minimal Residual Disease Testing for Solid Tumor Cancers" billing articles list 0340U. Listing a code is not a coverage stance, and we do not present it as one. claim 72verified claim 73verified
• Why a payer might still care: If MolDX's technical assessment requires a test's limit of detection to be shown on material of known variant allele fraction, then the laboratories you cover need material like this to get their tests assessed — without you paying for it. Nobody working on this has read that requirement in the LCD (local coverage determination) text. claim 137unconfirmed

Beyond intended use

Any message above that asserts a population, setting, duration or outcome the intended use does not state. None. is a valid answer and the honest one for most candidates. An absent section is a failure.

None. This is the set where the temptation to exceed the indication is strongest — a payer audience invites a patient-outcome or cost-offset story, and the customer's test has one to borrow. Checked and refused:

1. No outcome is claimed. No message says the material improves MRD test accuracy for patients, changes a recurrence call, or reduces downstream spend. The intended use is analytical performance monitoring and excludes individual patient results. A line saying so to the payer directly ("no change in any patient's result, treatment or outcome, and no saving") was drafted and deliberately kept out of ## Messages: it is a restatement of the indication rather than a proposition any claim substantiates, and tagging it to an unrelated verified claim would have padded the verified count. Whoever says this set out loud should still say it.
2. "Why a payer might still care" is conditional and analytical. It speaks only to whether a coverage process for the customer's test requires known-VAF (variant allele frequency) material for limit-of-detection work — which is assay validation, inside the indication — and it says the text has not been read. It must not be rewritten as "payers require this product".
3. The customer's money is never presented as the product's. The 0340U rate, volume and MolDX listings appear as the payment this product sits inside, never as its price, market or coverage.

What we cannot say yet

Every message above whose backing is not verified. The checker enforces set equality — exactly these lines, no more and no fewer.

• Billed under: "no code applies, and none is achievable" is a forward-looking negative that no database settles; the product has no code to look up — claim 55unconfirmed claim 14unconfirmed
• Budget impact: the same forward-looking negative; that the control's cost is absorbed with no add-on is structural reasoning, not a lookup — claim 55unconfirmed
• Why a payer might still care: L38779 (a Medicare local coverage determination number)'s analytical-validity criteria are unread, as are the MolDX technical-assessment FAQs and the BLOODPAC recommendation that would bear on it — claim 137unconfirmed